Tcg Crossover Gp Ii, Llc Acquires 106,658 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Tcg Crossover Gp Ii, Llc acquired 106,658 shares of the firm’s stock in a transaction that occurred on Tuesday, March 24th. The shares were bought at an average price of $24.69 per share, with a total value of $2,633,386.02. Following the completion of the purchase, the insider directly owned 736,554 shares in the company, valued at $18,185,518.26. The trade was a 16.93% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Tcg Crossover Gp Ii, Llc also recently made the following trade(s):

• On Monday, March 23rd, Tcg Crossover Gp Ii, Llc bought 15,223 shares of Surrozen stock. The stock was bought at an average price of $24.90 per share, for a total transaction of $379,052.70.
• On Monday, March 16th, Tcg Crossover Gp Ii, Llc bought 1,190 shares of Surrozen stock. The stock was purchased at an average price of $24.99 per share, with a total value of $29,738.10.
• On Friday, March 13th, Tcg Crossover Gp Ii, Llc purchased 35,433 shares of Surrozen stock. The shares were purchased at an average cost of $24.88 per share, with a total value of $881,573.04.
• On Thursday, March 12th, Tcg Crossover Gp Ii, Llc purchased 12,374 shares of Surrozen stock. The shares were purchased at an average cost of $24.99 per share, with a total value of $309,226.26.
• On Thursday, February 12th, Tcg Crossover Gp Ii, Llc purchased 1,093 shares of Surrozen stock. The stock was purchased at an average price of $23.86 per share, for a total transaction of $26,078.98.
• On Wednesday, February 11th, Tcg Crossover Gp Ii, Llc acquired 17,763 shares of Surrozen stock. The stock was purchased at an average cost of $23.57 per share, for a total transaction of $418,673.91.
• On Tuesday, February 3rd, Tcg Crossover Gp Ii, Llc acquired 4,355 shares of Surrozen stock. The shares were purchased at an average price of $21.94 per share, with a total value of $95,548.70.
• On Monday, February 2nd, Tcg Crossover Gp Ii, Llc bought 731 shares of Surrozen stock. The shares were purchased at an average cost of $21.38 per share, with a total value of $15,628.78.
• On Friday, January 30th, Tcg Crossover Gp Ii, Llc bought 4,271 shares of Surrozen stock. The shares were purchased at an average cost of $21.39 per share, with a total value of $91,356.69.

Surrozen Stock Up 7.1%

Shares of SRZN opened at $28.00 on Friday. The company has a 50 day moving average of $24.50 and a two-hundred day moving average of $18.87. Surrozen, Inc. has a twelve month low of $5.90 and a twelve month high of $29.59. The company has a market cap of $239.96 million, a price-to-earnings ratio of -0.84 and a beta of 0.53.

Surrozen (NASDAQ:SRZN) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($7.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.29) by ($6.30). Surrozen had a negative return on equity of 1,240.42% and a negative net margin of 7,476.67%.The business had revenue of $0.53 million for the quarter, compared to analyst estimates of $0.66 million. On average, sell-side analysts expect that Surrozen, Inc. will post -8.49 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. raised its stake in shares of Surrozen by 50.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after purchasing an additional 500 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in Surrozen in the fourth quarter valued at approximately $99,000. Citadel Advisors LLC boosted its position in Surrozen by 32.8% in the third quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the last quarter. Marshall Wace LLP acquired a new position in Surrozen in the 4th quarter worth approximately $247,000. Finally, Geode Capital Management LLC increased its holdings in Surrozen by 22.6% in the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after buying an additional 5,702 shares during the period. 66.57% of the stock is owned by institutional investors and hedge funds.

Key Surrozen News

Here are the key news stories impacting Surrozen this week:

• Positive Sentiment: Large insider buys by major shareholder TCG Crossover GP II — the fund bought 106,658 shares on March 24 (~$24.69 avg) and has repeatedly purchased stock in March, signaling strong insider conviction that can support the share price. SEC Filing
• Positive Sentiment: Additional TCG purchase: 15,223 shares on March 23 (~$24.90 avg), a follow-on buy that reinforces the insider buying narrative. InsiderTrades article
• Positive Sentiment: HC Wainwright reiterated a “Buy”, raised multi-quarter and multi-year EPS projections (less negative) and set a $36 price target — a constructive analyst view that can attract demand. Article
• Positive Sentiment: Cantor Fitzgerald assigned an “Overweight” rating with a higher price target (reported this week), providing another institutional buy-side signal. Article
• Neutral Sentiment: Institutional ownership is high (many hedge funds hold SRZN) and several institutions increased positions in recent quarters — supportive for liquidity but not an immediate catalyst.
• Negative Sentiment: Lifesci Capital cut multiple near-term EPS estimates (Q1–Q4 2026 and FY2026), making its outlook more pessimistic and creating downside pressure for sentiment. MarketBeat coverage
• Negative Sentiment: Recent quarterly results (reported March 23) were a significant miss (EPS deeply negative vs. expectations) and the company remains loss-making with volatile margins — a fundamental risk that keeps shares speculative despite positive headlines. Earnings detail

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Surrozen in a research note on Thursday, January 22nd. Wall Street Zen upgraded Surrozen to a “sell” rating in a research note on Friday, November 28th. Cantor Fitzgerald restated an “overweight” rating and set a $40.00 price objective on shares of Surrozen in a report on Tuesday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $36.00 price objective (up from $32.00) on shares of Surrozen in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Surrozen currently has a consensus rating of “Moderate Buy” and an average target price of $38.00.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.